Literature DB >> 1402142

Tolerance of intraperitoneal chemohyperthermia with mitomycin C: in vivo study in dogs.

F N Gilly1, P Y Carry, A C Sayag, G Panteix, M Manchon, A Rochette, J L Peix, J Baulieux, I James, G Braillon.   

Abstract

Tolerance of intraperitoneal chemohyperthermia (IPCH) with mitomycin C (2 mg/kg) by irrigation of the peritoneal cavity via a closed circuit system was evaluated in Beagle dogs for possible use in the management of human peritoneal carcinomatosis. Of dogs, 24 underwent three digestive anastomoses each. They were randomized into three groups: control (n = 6), intraperitoneal hyperthermia (n = 8) and IPCH (n = 10). Peritoneal temperatures were maintained between 41-43 degrees C for 60 min. Tolerance was evaluated through clinical follow-up, biological samples (serum electrolytes, blood counts and serum enzymes), histological examinations and post-mortem macro- and microscopic controls of anastomosis. Mortality and morbidity rates were not different in the three groups. No anastomotic leakage occurred. Evidence of biological toxicity was minimal. Histological examinations showed no definitive tissue damage. IPCH appears to be a safe and reliable device in dogs. Plans to combine IPCH with MMC in surgical resection of patients with peritoneal carcinomatosis are underway.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1402142     DOI: 10.3109/02656739209038001

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  2 in total

1.  Treatment of malignant peritoneal effusion in digestive and ovarian cancer.

Authors:  F N Gilly; P Y Carry; A Brachet; A C Sayag; G Panteix; B Salle; J Bienvenu; V Banssillon; G Burgard; M Manchon
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

Review 2.  Peritoneal carcinomatosis of colorectal cancer: incidence, prognosis, and treatment modalities.

Authors:  C Knorr; B Reingruber; T Meyer; W Hohenberger; C Stremmel
Journal:  Int J Colorectal Dis       Date:  2003-08-29       Impact factor: 2.571

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.